Town & Country Bank & Trust CO dba First Bankers Trust CO cut its stake in shares of Zoetis Inc (NYSE:ZTS) by 50.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,035 shares of the company’s stock after selling 5,085 shares during the quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Zoetis were worth $507,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Berman Capital Advisors LLC acquired a new position in shares of Zoetis in the fourth quarter valued at approximately $26,000. Athena Capital Advisors LLC purchased a new stake in shares of Zoetis in the fourth quarter valued at $29,000. Resources Investment Advisors Inc. purchased a new position in Zoetis during the fourth quarter worth about $31,000. Lavaca Capital LLC purchased a new position in Zoetis during the fourth quarter worth about $32,000. Finally, Acima Private Wealth LLC purchased a new position in shares of Zoetis in the 4th quarter worth about $34,000. 90.93% of the stock is owned by institutional investors and hedge funds.

In other news, insider Clinton A. Jr. Lewis sold 6,125 shares of Zoetis stock in a transaction on Monday, January 14th. The stock was sold at an average price of $85.21, for a total transaction of $521,911.25. Following the transaction, the insider now directly owns 48,070 shares in the company, valued at approximately $4,096,044.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Juan Ramon Alaix sold 312,109 shares of Zoetis stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $94.06, for a total value of $29,356,972.54. The disclosure for this sale can be found here. Insiders have sold a total of 410,334 shares of company stock worth $38,574,260 in the last ninety days. 0.35% of the stock is owned by company insiders.

A number of equities research analysts have recently issued reports on the company. Credit Suisse Group increased their target price on Zoetis from $102.00 to $112.00 and gave the company an “outperform” rating in a research note on Tuesday, April 2nd. UBS Group started coverage on Zoetis in a report on Wednesday, March 20th. They set a “neutral” rating on the stock. SunTrust Banks started coverage on Zoetis in a report on Tuesday, March 19th. They set a “hold” rating and a $100.00 target price on the stock. Stifel Nicolaus raised Zoetis from a “hold” rating to a “buy” rating and increased their target price for the stock from $97.00 to $110.00 in a report on Monday, March 4th. Finally, Zacks Investment Research raised Zoetis from a “sell” rating to a “hold” rating in a report on Saturday, February 16th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $100.57.

Shares of NYSE ZTS traded down $0.41 during mid-day trading on Thursday, hitting $100.92. The company had a trading volume of 46,904 shares, compared to its average volume of 1,973,971. The company has a market cap of $48.56 billion, a price-to-earnings ratio of 32.26, a price-to-earnings-growth ratio of 1.84 and a beta of 0.93. Zoetis Inc has a 12 month low of $77.00 and a 12 month high of $103.33. The company has a current ratio of 3.60, a quick ratio of 2.46 and a debt-to-equity ratio of 2.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 14th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.02. The business had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.53 billion. Zoetis had a return on equity of 73.85% and a net margin of 24.51%. The business’s revenue was up 7.1% on a year-over-year basis. During the same quarter last year, the business posted $0.69 EPS. As a group, equities analysts forecast that Zoetis Inc will post 3.46 earnings per share for the current fiscal year.

Zoetis declared that its Board of Directors has initiated a stock repurchase plan on Wednesday, December 12th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 4.7% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Shareholders of record on Thursday, April 18th will be paid a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a yield of 0.65%. The ex-dividend date is Wednesday, April 17th. Zoetis’s payout ratio is currently 21.09%.

TRADEMARK VIOLATION WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/town-country-bank-trust-co-dba-first-bankers-trust-co-has-507000-stake-in-zoetis-inc-zts/2955645.html.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Further Reading: Call Option Volume

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.